Interleukin-6, a marker of preservation injury in clinical lung transplantation

J Heart Lung Transplant. 1992 Nov-Dec;11(6):1017-24.

Abstract

Interleukin-6 (IL-6) is one of the cytokines produced by human alveolar macrophages, lung parenchyma, and other cells in response to injury and infection. We hypothesized that IL-6 is released from poorly preserved lung grafts and may serve as a marker of preservation injury. Sixteen patients who received lung allografts were enrolled in this study. The average ischemic time was 284 +/- 78 minutes. Serum IL-6 level was measured before and at 4 and 24 hours after reperfusion of the grafts by an enzyme-linked immunosorbent assay. Preservation injury was assessed by (1) the need for prolonged intubation (> 7 days), (2) the arterial/alveolar oxygen tension ratio (PaO2/PAO2 ratio) at 4 hours after graft reperfusion (only in heart-lung or double lung recipients), (3) the presence of diffuse alveolar damage on first lung biopsy, and (4) the 30-day graft survival rate. IL-6 level peaked at 4 hours after reperfusion and returned to baseline at 24 hours. The patients were divided into group I (n = 6) and group II (n = 10), depending on whether the 4-hour IL-6 level was more than 1000 pg/ml or less than 500 pg/ml, respectively. Group I patients required longer intubation (p < 0.01) and had a lower PaO2/PAO2 ratio (p < 0.001), more diffuse alveolar damage (p < 0.01), and a lower graft survival rate (p < 0.01) than those of group II. No bacterial, fungal, or viral infection was found during postoperative week 1 in either group.(ABSTRACT TRUNCATED AT 250 WORDS)

MeSH terms

  • Adult
  • Enzyme-Linked Immunosorbent Assay
  • Extracorporeal Membrane Oxygenation
  • Female
  • Graft Survival*
  • Humans
  • Interleukin-6 / blood*
  • Intubation, Intratracheal
  • Lung / pathology*
  • Lung Transplantation / immunology*
  • Lung Transplantation / pathology
  • Male
  • Organ Preservation / adverse effects*
  • Time Factors
  • Treatment Outcome

Substances

  • Interleukin-6